SCHEMBL27218699

SCHEMBL27218699

Nc1cc(O)nc(SCc2nc(-c3ccc4c(c3)OCO4)no2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.57
▸ NPC1 O15118 6/20 0.57
▸ SMN1; SMN2 Q16637 5/20 0.57
▸ LMNA P02545 3/20 0.57
▸ HTT P42858 1/20 0.57
▸ CHRM2 P08172 1/20 0.43
▸ CHRM5 P08912 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ PKM P14618 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ MAPK1 P28482 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ GAA P10253 2/20 0.42
▸ MAPT P10636 4/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ADORA1 P30542 3/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ ADORA2B P29275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218761 0.87 RAB9A (0.64) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218815 0.87 RAB9A (0.49) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218787 0.85 RAB9A (0.54) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218738 0.85 RXFP1 (0.47) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218710 0.85 LMNA (0.46) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218860 0.85 RAB9A (0.47) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218773 0.84 NPC1 (0.45) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218770 0.83 CHRM2 (0.45) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218790 0.82 RAB9A (0.48) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL31494458 0.81 RAB9A (0.54) RAB9ANPC1SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 RAB9A 2474/4885NPC1 781/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback